Risk Intelligence
New entrant competition in India
View Risks →Apollo Tyres reported a solid Q2 FY26 with consolidated revenue of INR 68.3 billion (+6% YoY) and EBITDA margin of 14.9% (+130 bps YoY), driven by strong India performance and recovery in exports.
Financial stats pending filing verification
Apollo Tyres reported a solid Q2 FY26 with consolidated revenue of INR 68.3 billion (+6% YoY) and EBITDA margin of 14.9% (+130 bps YoY), driven by strong India performance and recovery in exports. India revenue grew 6% to INR 47.1 billion with EBITDA margin of 15.3%, aided by GST rationalization benefits and volume growth in replacement and OEM segments. Europe revenue grew 4% YoY to EUR 177 million, though demand remains challenging. Management expects healthy demand momentum in H2, with October showing strong growth. Raw material costs are expected to remain range-bound. Risks include competitive intensity from new entrants and uncertain European demand recovery.
अपोलो टायर्स ने वित्त वर्ष 2026 की दूसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 68.3 अरब रुपये रही, जो पिछले साल से 6% ज्यादा है। कमाई पर मुनाफा (EBITDA मार्जिन) 14.9% रहा, जो पिछले साल से 1.3% बेहतर है। यह भारत में मजबूत बिक्री और निर्यात में सुधार के कारण हुआ। भारत में कमाई 6% बढ़कर 47.1 अरब रुपये हुई, जिसमें मुनाफा 15.3% रहा। इसका कारण जीएसटी में छूट और टायर बदलने व नई गाड़ियों की बिक्री बढ़ना है। यूरोप में कमाई 4% बढ़ी, लेकिन मांग कमजोर है। कंपनी को अक्टूबर में अच्छी बिक्री देखने को मिली और आगे भी मांग बनी रहने की उम्मीद है। कच्चे माल की कीमतें स्थिर रहने का अनुमान है। जोखिमों में नई कंपनियों से प्रतिस्पर्धा और यूरोप में अनिश्चित मांग शामिल है।
New entrant competition in India
View Risks →Full transcript text is available on this route.
Read Transcript →Overall volume growth in India for Q2 FY26, driven by farm and two/three-wheeler segments.
Ultra-high performance tire mix in Europe increased to 49% from 46% last year, supporting premiumization.
Estimated market share in India TBR replacement segment, with share loss arrested.
Estimated industry-leading market share in India PCR replacement segment.
Management expects Q3 revenue growth to be at least at Q2 levels, driven by GST benefits and brand investments.
Profitability expected to remain at current levels or improve, supported by stable raw material costs and operating leverage.
Replacement demand expected to improve from current low levels to mid-to-high single digit growth.
Production closure at Enschede plant expected by end June 2026, with payback period of about two years on EUR 55 million cash costs.
Management expects healthy replacement demand momentum in Q4, with signs of further pickup beyond current levels.
RM costs expected to be range-bound in Q4, around similar levels as Q3, indicating plateauing.
Given market situation, no price increase is planned in the near term; will continue to assess.
Next year's capex will increase above maintenance level (~₹700-750 cr) by about ₹800 cr for PCR capacity expansion in India and Europe.
A financially strong new player is entering PCR and TBR segments, potentially increasing competitive intensity and pricing pressure.
European market remains challenging with low single-digit growth expected; recovery is not yet assured.
While raw materials are currently stable, any upturn could pressure margins, especially given competitive pricing dynamics.
Apollo lost ground in PCR OEM shares due to not bidding for certain unprofitable businesses, which may impact future volumes.
Management cited competitive intensity as reason for not planning price hikes despite margin pressure.
Exports were flattish due to weak demand in certain markets and high logistics costs, with peers outperforming.
India gross margin contracted ~300bps QoQ partly due to consumption of high-cost inventory; normalization expected but uncertain.
Management expects Q3 revenue growth to be at least at Q2 levels, driven by GST benefits and brand investments.
A financially strong new player is entering PCR and TBR segments, potentially increasing competitive intensity and pricing pressure.
View Risks →